# Current potential biomarkers for Alzheimer’s disease, Parkinson’s disease and amyotrophic lateral sclerosis: review of literature

## TL;DR

This paper reviews potential biomarkers for Alzheimer’s, Parkinson’s, and ALS, focusing on their use in diagnosis, progression, prognosis, and treatment.

## Contribution

The paper provides a systematic review of recent advances in biomarkers for three major neurodegenerative diseases.

## Key findings

- Blood, cerebrospinal fluid, and neuroimaging are key sources of potential biomarkers.
- Emerging non-invasive indicators are gaining attention for their diagnostic potential.
- Current evidence highlights the urgent need for reliable biomarkers in disease management.

## Abstract

Alzheimer’s disease (AD), Parkinson’s disease (PD) and amyotrophic lateral sclerosis (ALS) are several common neurodegenerative diseases (NDs). At present, is the lack of effective diagnosis, progression, prognosis and therapeutic biomarkers. it is a urgent demand to search the relevant confident biomarkers.

This review systematically analysed the potential biomarkers of blood, cerebrospinal fluid, neuroimaing and emerging non-invasive indicators, and synthesises current evidences on the biomarkers of AD, PD and ALS about diagnosis, progression, prognosis and therapeutic, especially diagnosis biomarkers.

In this review, we focus on discussing relevant diagnosis, progression, prognosis and therapeutic biomarkers for AD, PD and ALS in recent years, and prospecting the possible future directions of relevant biomarkers.